Professor of Endocrinology
Newer antihyperglycemic drugs have specific advantages in terms of risk of hypoglycemia, impact on body weight, cardiovascular and renal protection over traditional agents, but are more expensive. Strategies based on the price structure of these medications will be explored to reduce the cost differences between various strategies.
A revised figure helping the adjustment of antiyperglycemic agents to eGFR will be presented.
The impact of age and functional status on glycemic goals and on the choice of a therapy according to the most recent Diabetes Canada guidelines will be reviewed with case studies.
As a result of attending this session, participants will be able to: